The structural profiles are close, with Ipsen carrying a narrow edge on growth. Hikma Pharmaceuticals still leads on profitability and valuation, which keeps the comparison from looking entirely one-sided. On the market side, Ipsen is in better shape — its trend is intact while Hikma Pharmaceuticals's trend has broken down. That puts structure and market broadly in agreement — Ipsen's lead looks more confirmed than conflicted.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the STOXX 600 universe, making them directly comparable.
This is not just a one-metric split: both growth and stability materially support the lead.
Both operate in: Drug Manufacturers - Specialty & Generic
This comparison is based on industry proximity, not on functional trajectory similarity. HIK.L and IPN.PA share the same industry classification.
For a similarity-based comparison, see how Hikma Pharmaceuticals and Ipsen each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
Ipsen S.A. occupies the cheaper side of the setup map, although Hikma Pharmaceuticals PLC still holds the stronger structural profile.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Earnings growth is one contributing factor within the growth lead.
Absolute pricing still looks more supportive for Hikma Pharmaceuticals, with a forward P/E that is 2.4 turns lower there.
The lead is built on both growth and stability — though profitability still provides a counterweight.
Break down the HIK.L vs IPN.PA comparison across all dimensions with the full interactive tool.
Explore how HIK.L and IPN.PA each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.